Labcorp Holdings (NYSE:LH) reported fourth-quarter 2025 revenue of $3.52 billion, contributing to full-year enterprise revenue of $13.95 billion, up 7.2% from the prior year.
Adjusted earnings per share for the full year climbed to $16.44 from $14.57 in 2024, reflecting improved margins and operational efficiencies across its diagnostics and biopharma laboratory services businesses.
Free cash flow for the year reached $1.21 billion, underscoring the company's strong cash generation capabilities amid ongoing investments in high-growth areas.
The results cap a year of strategic progress for Labcorp, which completed 13 transactions to bolster its capabilities, launched more than 130 new tests, and advanced its leadership in neurology diagnostics.
Notably, the company introduced the first FDA-cleared blood test for Alzheimer's disease assessment in primary care settings, developed in partnership with Roche Diagnostics and now widely available to aid early detection in patients with cognitive symptoms.
Labcorp also announced plans for a significant expansion of its Central Laboratory Services footprint, including a new purpose-built facility in Brownsburg, Indiana.
The multi-year project will feature more than 500,000 square feet of advanced laboratory and production space on a 50-acre campus, increasing capacity by about 40% over the current Indianapolis operations to support future demand in clinical trials and specialty testing.
Looking to 2026, Labcorp provided optimistic guidance, projecting enterprise revenue of $14.61 billion to $14.79 billion, representing midpoint growth of approximately 5.4%.